文献速递神经肿瘤小儿神经外科与脑积水

儿童与青少年室管膜瘤的分子图谱:基于二代测序panel的遗传变异识别

Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.
PubMed 文献 · J Neurooncol · 2021-09-27

该研究对61例儿童及青少年室管膜瘤样本(42例后颅窝、14例幕上、5例脊髓)使用OCCRA®二代测序panel进行分子检测。24例(39.3%)肿瘤中检出遗传变异,超过90%为致病或可能致病性变异,常见变异位于CIC、ASXL1和JAK2基因,此前未见室管膜瘤报道;1例幕上样本检出MN1-BEND2融合并重新分类为星形母细胞瘤,2例2岁以下患者检出YAP1-MAMLD1融合。

要点

  • OCCRA®panel在39.3%的儿童/青少年室管膜瘤中检出遗传变异。
  • CIC、ASXL1和JAK2变异为室管膜瘤中新报道的变异。
  • MN1-BEND2融合提示需重新分类为星形母细胞瘤。

核心结论

  • OCCRA®panel在儿童及青少年室管膜瘤中检出既往未报道的分子变异,提示识别遗传变异对患者预后判断和治疗方向具有临床意义。

研究设计与样本

  • 研究纳入61例初诊室管膜瘤患者样本,来自Pediatric Oncology Institute-GRAACC/UNIFESP。
  • 样本按CNS解剖分区分为后颅窝42例、幕上14例、脊髓5例。
  • 使用Thermo Fisher Scientific®的Oncomine Childhood Cancer Research Assay®(OCCRA®)panel进行二代测序检测肿瘤样本的体细胞遗传变异。

主要发现

  • 61例肿瘤中24例(39.3%)检出遗传变异,超过90%的变异为致病或可能致病性变异。
  • 最常见变异位于CIC、ASXL1和JAK2基因,此前未见室管膜瘤报道。
  • 1例幕上样本检出MN1-BEND2融合,该样本被重新分类为星形母细胞瘤。
  • 2例2岁以下患者检出YAP1-MAMLD1融合,该事件在幕上室管膜瘤中罕见且与良好预后相关。

临床怎么用

  • 对儿童及青少年室管膜瘤可考虑使用OCCRA®panel进行分子分型以辅助预后判断和治疗方向选择。
  • 检出MN1-BEND2融合时需考虑星形母细胞瘤的鉴别诊断并重新分类。
  • 检出YAP1-MAMLD1融合的幕上室管膜瘤患者可能提示良好预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ependymoma (EPN) accounts for approximately 10% of all primary central nervous system (CNS) tumors in children and in most cases, chemotherapy is ineffective and treatment remains challenging. We investigated molecular alterations, with a potential prognostic marker and therapeutic target in EPNs of childhood and adolescence, using a next-generation sequencing (NGS) panel specific for pediatric neoplasms. METHODS: We selected 61 samples with initial diagnosis of EPN from patients treated at Pediatric Oncology Institute-GRAACC/UNIFESP. All samples were divided according to the anatomical compartment of the CNS - 42 posterior fossa (PF), 14 supratentorial (ST), and five spinal (SP). NGS was performed to identify somatic genetic variants in tumor samples using the Oncomine Childhood Cancer Research Assay® (OCCRA®) panel, from Thermo Fisher Scientific®. RESULTS: Genetic variants were identified in 24 of 61 (39.3%) tumors and over 90% of all variants were pathogenic or likely pathogenic. The most commonly variants detected were in CIC, ASXL1, and JAK2 genes and have not been reported in EPN yet. MN1-BEND2 fusion, alteration recently described in a new CNS tumor type, was identified in one ST sample that was reclassified as astroblastoma. Additionally, YAP1-MAMLD1 fusion, a rare event associated with good outcome in ST-EPN, was observed in two patients diagnosed under 2 years old. CONCLUSIONS: Molecular profiling by the OCCRA® panel showed novel alterations in pediatric and adolescent EPNs, which highlights the clinical importance in identifying genetic variants for patients' prognosis and therapeutic orientation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Cabral de Carvalho Corrêa D, Tesser-Gamba F, Dias Oliveira I, et al. Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel. J Neurooncol. 2021. PMID: 34570300. doi:10.1007/s11060-021-03848-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。